title: Maternal characteristics influencing the development of gestational diabetes in obese women receiving 17-alpha-hydroxyprogesterone caproate.
abstract: OBJECTIVE
  Gestational diabetes (GDM) and obesity portend a high risk for subsequent type 2 diabetes. We examined maternal factors influencing the development of gestational diabetes (GDM) in obese women receiving 17-alpha-hydroxyprogesterone caproate (17OHPC) for preterm delivery prevention.
  
  
  METHODS
  Retrospectively identified were 899 singleton pregnancies with maternal prepregnancy body mass indices of ≥30 kg/m(2) enrolled for either 17OHPC weekly administration (study group) or daily uterine monitoring and nursing assessment (control group). Patients with history of diabetes type 1, 2, or GDM were excluded. Maternal characteristics were compared between groups and for women with and without development of GDM. A logistic regression model was performed on incidence of GDM, controlling for significant univariate factors.
  
  
  RESULTS
  The overall incidence of GDM in the 899 obese women studied was 11.9%. The incidence of GDM in the study group (n = 491) was 13.8% versus 9.6% in the control group (n = 408) (P = 0.048). Aside from earlier initiation of 17OHP and advanced maternal age, other factors including African American race, differing degrees of obesity, and use of tocolysis were not significant risks for the development of GDM.
  
  
  CONCLUSIONS
  In obese women with age greater than 35 years, earlier initiation of 17OHPC may increase the risk for GDM.
authors.affiliation: Department of Obstetrics and Gynecology, University of Florida College of Medicine, 1600 SW Archer Road, P.O. Box 100294, Gainesville, FL 32610-0294, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Egerman
authors.affiliation: University of Tennessee Health Science Center, Memphis, TN 38163, USA.
authors.forename: Risa
authors.initials: R
authors.lastname: Ramsey
authors.affiliation: Department of Clinical Research, Alere, Women's & Children's Health, Atlanta, GA 30339, USA.
authors.forename: Niki
authors.initials: N
authors.lastname: Istwan
authors.affiliation: Department of Clinical Research, Alere, Women's & Children's Health, Atlanta, GA 30339, USA.
authors.forename: Debbie
authors.initials: D
authors.lastname: Rhea
authors.affiliation: Department of Clinical Research, Alere, Women's & Children's Health, Atlanta, GA 30339, USA.
authors.forename: Gary
authors.initials: G
authors.lastname: Stanziano
mesh_terms: D000077713:17 alpha-Hydroxyprogesterone Caproate; D000328:Adult; D015992:Body Mass Index; D016640:Diabetes, Gestational / Q000139:chemically induced* / Q000453:epidemiology; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000008:administration & dosage / Q000009:adverse effects*; D007273:Injections, Intramuscular; D008423:Maternal Age; D009765:Obesity / Q000150:complications / Q000453:epidemiology / Q000378:metabolism*; D011247:Pregnancy; D047928:Premature Birth / Q000517:prevention & control*; D012189:Retrospective Studies; D012307:Risk Factors; D015149:Tocolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D014481:United States / Q000453:epidemiology
chemical_list: D006908:Hydroxyprogesterones; D015149:Tocolytic Agents; D000077713:17 alpha-Hydroxyprogesterone Caproate